News / American Regent
Shirley, NY – October 15, 2024:
American Regent announces the launch and availability of 30 mL Epinephrine Injection, USP.
Melville, NY – September 9, 2024:
Learn more about the St. John’s University and American Regent Post-Doctoral Pharmaceutical Industry Fellowship by downloading our brochure. Information on how to apply to our program as well as key deadlines are included.
Shirley, NY – July 2, 2024:
American Regent announces the launch and availability of Sodium Phosphates Injection, USP, which is FDA-approved and therapeutically equivalent to Sodium Phosphates.
Shirley, NY – September 27, 2023:
American Regent has received a Novaplus Program Excellence Award from Vizient, Inc., the nation’s largest provider-driven health care performance improvement company. The recognition was announced at the 2023 Vizient Connections Summit, held September 18-21 in Las Vegas.
Shirley, NY–August 26, 2023: American Regent, Inc., a Daiichi Sankyo Group company, today announced results from the phase 3 HEART-FID trial of INJECTAFER (ferric carboxymaltose injection) for the treatment of iron deficiency in adult heart failure patients with reduced ejection fraction (HFrEF).
Basking Ridge, NJ and Shirley, NY – June 5, 2023: Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, today announced that the U.S. Food and Drug Administration (FDA) approved INJECTAFER® (ferric carboxymaltose injection) for the treatment of iron deficiency in adult patients with heart failure categorized as New York Heart Association class II/III to improve exercise capacity.
Melville, NY – May 2, 2023: American Regent® is pleased to announce the launch of Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound).
Melville, NY – March 23, 2023: American Regent announces the launch of sulfite-free Epinephrine Injection, USP.
Shirley, NY – American Regent, Inc., a U.S. manufacturer of pharmaceuticals for human and veterinary use with manufacturing sites in New York and Ohio, today announced it acquired HBT Labs, Inc. based in California.
Melville, NY – August 9, 2022: American Regent, Inc. has announced the launch of Atropine Sulfate Injection, USP, a longstanding injectable medication, now with FDA approval.
Melville, NY – March 31, 2022: American Regent, Inc. is pleased to announce the launch of Selenious Acid Injection, USP in a new concentration and vial size.
Melville, NY – February 3, 2022: American Regent announces the introduction and availability of FDA-approved Vasopressin Injection, USP. Vasopressin is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
For patients as young as one year of age who have intolerance to, or have had an unsatisfactory response to, oral iron, Injectafer may now be administered for IDA treatment1
Basking Ridge, N.J. and Shirley, N.Y. (December 15, 2021) – Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, today announced that the U.S. Food and Drug Administration (FDA) has approved Injectafer for pediatric patients (who are 1 year of age or older) with iron deficiency anemia (IDA) who are intolerant to oral iron or who have had an unsatisfactory response to oral iron.
Melville, NY – September 2, 2021: American Regent, Inc. introduces FDA-approved Multrys™ (trace elements injection 4*, USP). Multrys™ is indicated in neonatal and pediatric patients weighing less than 10 kg as a source of zinc, copper, manganese, and selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.
Basking Ridge, N.J. and Shirley, N.Y. (May 6, 2021): Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, today announced that the U.S. Food and Drug Administration (FDA) has approved a single 1000 mg dose option of Injectafer® (ferric carboxymaltose injection), an iron replacement product, for the treatment of iron deficiency anemia (IDA) in adult patients who have intolerance to oral iron, have had unsatisfactory response to oral iron, or have non-dialysis dependent chronic kidney disease (CKD).1
Shirley, NY – April 1, 2021: Paul Diolosa assumed the role of President and CEO of American Regent, Inc., a Daiichi Sankyo Group company, effective today.